logo
EN 简体 繁体
EN 简体 繁体
  • About Us
    • Company Overview
    • Milestones
    • Our Team
    • Investors
    • Partnership & Recognition
    • Contact Us
  • Pipeline & Products
    • Pipeline
      • Rare Oncology
      • Rare Diseases
      • Gene Therapy
      • Other Onc.
    • Approved Products
      • Hunterase®
      • Nerlynx®
      • Caphosol®
  • Investors
    • Information Disclosure
      • Listing Documents
      • Financial Reports
      • Announcements & Circulars
    • Corporate Governance
    • Stock Information
    • Presentations & Webcasts
    • Analyst Coverage
    • Financial Calendar
    • Email Alert and IR Contact
  • Media & News
    • Media Reports
    • Press Release
  • Corporate Culture & Career
    • Corporate Culture
    • Open Positions
Financial Reports
2022
2022 Interim Report
Interim Results Announcement for the Six Months Ended 30 June,2022
2021
2021 Annual Report
Annual Results Announcement for The Year Ended December 31, 2021
  • About Us
    • Company Overview
    • Milestones
    • Our Team
    • Investors
    • Partnership & Recognition
    • Contact Us
  • Pipeline & Products
    • Pipeline
      • Rare Oncology
      • Rare Diseases
      • Gene Therapy
      • Other Onc.
    • Approved Products
      • Hunterase®
      • Nerlynx®
      • Caphosol®
  • Investors
    • Information Disclosure
      • Listing Documents
      • Financial Reports
      • Announcements & Circulars
    • Corporate Governance
    • Stock Information
    • Presentations & Webcasts
    • Analyst Coverage
    • Financial Calendar
    • Email Alert and IR Contact
  • Media & News
    • Media Reports
    • Press Release
  • Corporate Culture & Career
    • Corporate Culture
    • Open Positions
Privacy Policy  Copyright ©:CANbridge Life Sciences Ltd.   ICP:12036158-1  京公网安备11010502044059号 互联网药品信息服务资格证编号(京)-非经营性-2021-0065  Developed by Euroland IR